Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction

Patent metadata

Field	Value
Publication number	US-10451641-B2
Application number	US-201615557621-A
Country	US
Kind code	B2
Filing date	Mar 14, 2016
Priority date	Mar 13, 2015
Publication date	Oct 22, 2019
Grant date	Oct 22, 2019

Abstract

Disclosed herein are compositions and methods for targeted metabolomics profiling to provide absolute quantification of a broad array of metabolic intermediates of fatty acids, amino acids, and carbohydrate metabolism for HFpEF. In an aspect, the disclosure relates to a method for assessing risk of death or a major adverse cardiac event (MACE) in a subject diagnosed with heart failure with preserved ejection fraction (HFpEF). The method may include (a) determining in a sample from the subject the level of each metabolite in at least one factor, wherein the factor is selected from the group consisting of factor 1, factor 3, factor 4, factor 5, factor 10, factor 12, and factor 14; and (b) comparing the level of each metabolite in the sample to a standard, wherein the level of the metabolite in the subject relative to a standard is indicative of the risk of death or MACE in the subject.

First claim

The invention claimed is:

1. A method for treating a subject diagnosed with heart failure with preserved ejection fraction (HFpEF) and having an increased risk of death or a major adverse cardiac event (MACE), the method comprising:
(a) determining in a sample from the subject the level of each metabolite in at least one factor, the determined level being different from the level of the metabolite in a standard sample, wherein the factor is selected from factor 1, factor 3, factor 4, factor 5, factor 10, factor 12, and factor 14,
wherein factor 1 consists of medium-chain acylcarnitines,
wherein factor 3 consists of short-chain dicarboxylacylcarnitines,
wherein factor 4 consists of long-chain acylcarnitines, wherein factor 5 consists of ketone related metabolites,
wherein factor 10 consists of glycine, ornithine, and tiglyl-carnitine,
wherein factor 12 consists of 3-hydroxy-linoleyl-carnitine, and
wherein factor 14 consists of docosanoyl-carnitine;
(b) determining that the subject has an increased risk of death or MACE based on the determined level of each metabolite in the subject in step (a): and
(c) administering to the subject a treatment for heart failure comprising at least one therapy selected from angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta blocker, aldosterone antagonist, hydralazine, nitrate, pacemaker, implantable cardiac defibrillator, heart transplant, or a combination thereof.

2. A method for treating a subject diagnosed with HFpEF and having an increased risk of death or MACE, the method comprising:
(a) determining in a sample from the subject the level of each metabolite in at least one factor selected from factor 1, factor 3, factor 4, factor 5, factor 10, factor 12, and factor 14,
wherein factor 1 consists of medium-chain acylcarnitines,
wherein factor 3 consists of short-chain dicarboxylacylcarnitines, wherein factor 4 consists of long-chain acylcarnitines,
wherein factor 5 consists of ketone related metabolites,
wherein factor 10 consists of glycine, ornithine, and tiglyl-carnitine,
wherein factor 12 consists of 3-hydroxy-linoleyl-carnitine,
wherein factor 14 consists of docosanoyl-carnitine,
wherein the determined level of each metabolite multiplied by a scoring coefficient specific for each metabolite determines a weighted level of each metabolite, and wherein the weighted level of each metabolite in the factor added together yields a factor score in the subject that is different from the factor score of a non-HFpEF standard;
(b) determining that the subject has an increased risk of death or MACE based on the factor score in the subject determined in step (a); and
(c) administering to the subject a treatment for heart failure comprising at least one therapy selected from angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta blocker, aldosterone antagonist, hydralazine, nitrate, pacemaker, implantable cardiac defibrillator, heart transplant, or a combination thereof.

3. The method of claim 1 , wherein factor 1 consists of medium-chain acylcarnitines selected from C8, C10, C12, C14:1, C14, C16:2, C16:1, C14:2, C12:1, and C10:1 acylcarnitines,
wherein factor 3 consists of short-chain dicarboxylacylcarnitines selected from C5-DC, C6:1-DC/C8:1-OH, C8:1-DC, C6-DC, Ci4-DC/C4-DC, C10-OH/C8-DC, and C12-OH/C10-DC acylcarnitines and the amino acid citrulline,
wherein factor 4 consists of long-chain acylcarnitine related metabolites selected from C18:1, C18:2, C18, C16, C20:4, and C16:1-OH/C14:1-DC acylcarnitines, and
wherein factor 5 consists of ketone related metabolites selected from ketones, ß-hydroxybutyrate, ß-hydroxybutyryl-carnitine, acetylcarnitine, and alanine.

4. The method of claim 1 , wherein the level of each metabolite in more than one factor is determined in step (a).

5. The method of claim 1 , wherein the level of each metabolite in two factors is determined in step (a).

6. The method of claim 1 , wherein the level of each metabolite in three factors is determined in step (a).

7. The method of claim 1 , wherein the level of each metabolite in four factors is determined in step (a).

8. The method of claim 1 , wherein the level of each metabolite in five factors is determined in step (a).

9. The method of claim 1 , wherein the level of each metabolite in six factors is determined in step (a).

10. The method of claim 1 , wherein the factor is selected from factor 1, factor 3, factor 4, factor 5, and factor 12, and wherein the determined level of each metabolite in the selected factor in the subject is greater than the level of the metabolite in a standard sample.

11. The method of claim 1 , wherein the factor is selected from factor 10 and factor 14, and wherein the determined level of each metabolite in the selected factor in the subject is less than the level of the metabolite in a standard sample.

12. The method of claim 2 , wherein the factor is selected from factor 1, factor 3, factor 4, factor 5, and factor 12, and wherein the factor score for the subject is greater than the factor score of a non-HFpEF standard.

13. The method of claim 2 , wherein the factor is selected from factor 10and factor 14, and wherein the factor score for the subject is less than the factor score of a non-HFpEF standard.

14. A method for treating heart failure with preserved ejection fraction (HFpEF) in a subject, the method comprising:
(a) determining in a sample from the subject the level of each metabolite in factor 4 that is greater than to the level in a standard sample, wherein factor 4 consists of long chain acylcarnitines;
(b) diagnosing the subject as having HFpEF based on the determined level of each metabolite in the subject in step (a) and
(c) administering to the subject a treatment for heart failure comprising at least one therapy selected from angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta blocker, aldosterone antagonist, hydralazine, nitrate, pacemaker, implantable cardiac defibrillator, heart transplant, or a combination thereof.

15. The method of claim 14 , wherein factor 4 consists of long chain acylcarnitines selected from C18:1, C18:2, C18, C16, C20:4, and C16:1-OH/C14:1-DC acylcarnitines.

16. The method of claim 1 , wherein the sample is blood.

17. The method of claim 1 , wherein the level of the metabolite is detected using mass spectrometry, or a colorimetric assay, or fluorometric assay.

Assignees

• Univ Duke

Inventors

• Shah Svati

Classifications

• A61B5/1468

  using chemical or electrochemical methods, e.g. by polarographic means · CPC title

• A61B5/4842

  Monitoring progression or stage of a disease · CPC title

• A61B5/00

  Measuring for diagnostic purposes (radiation diagnosis A61B6/00; diagnosis by ultrasonic, sonic or infrasonic waves A61B8/00); Identification of persons · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2800/325

  Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure · CPC title